- Home
- JAZZ vs CZR Comparison
JAZZ vs CZR Comparison
Compare JAZZ & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- CZR
- Stock Information
- Founded
- JAZZ 2003
- CZR 1937
- Country
- JAZZ Ireland
- CZR United States
- Employees
- JAZZ 2800
- CZR N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- CZR Hotels/Resorts
- Sector
- JAZZ Health Care
- CZR Consumer Discretionary
- Exchange
- JAZZ Nasdaq
- CZR Nasdaq
- Market Cap
- JAZZ 7.0B
- CZR 6.2B
- IPO Year
- JAZZ 2007
- CZR 1989
- Fundamental
- Price
- JAZZ $108.94
- CZR $25.13
- Analyst Decision
- JAZZ Strong Buy
- CZR Strong Buy
- Analyst Count
- JAZZ 12
- CZR 14
- Target Price
- JAZZ $183.00
- CZR $42.93
- AVG Volume (30 Days)
- JAZZ 628.2K
- CZR 6.0M
- Earning Date
- JAZZ 08-05-2025
- CZR 07-29-2025
- Dividend Yield
- JAZZ N/A
- CZR N/A
- EPS Growth
- JAZZ 49.21
- CZR N/A
- EPS
- JAZZ 7.51
- CZR N/A
- Revenue
- JAZZ $4,064,808,000.00
- CZR $11,374,000,000.00
- Revenue This Year
- JAZZ $6.10
- CZR $3.33
- Revenue Next Year
- JAZZ $5.07
- CZR $2.50
- P/E Ratio
- JAZZ $15.07
- CZR N/A
- Revenue Growth
- JAZZ 5.76
- CZR N/A
- 52 Week Low
- JAZZ $95.49
- CZR $21.40
- 52 Week High
- JAZZ $148.06
- CZR $45.93
- Technical
- Relative Strength Index (RSI)
- JAZZ 48.58
- CZR 30.64
- Support Level
- JAZZ $112.17
- CZR $28.58
- Resistance Level
- JAZZ $117.39
- CZR $30.20
- Average True Range (ATR)
- JAZZ 2.77
- CZR 1.08
- MACD
- JAZZ -0.33
- CZR -0.60
- Stochastic Oscillator
- JAZZ 24.15
- CZR 3.76
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.